MIMS has been granted the CE marking, enabling market launch in Europe (March 20, 2017).
First in human study taking place in Dr. Agarwal's group of eye hospitals and Eye Research Center, Chennai, India (http://www.dragarwal.com) and the Sheba Medical Center, Tel Hashomer, Israel.
The study started in January 2015 and since its commencement, over 50 procedures have been carried out. Early indications from experience gained using the MIMS device and procedure in Glaucoma patients indicate that the MIMS device indeed reduces intraocular pressure (IOP) in patients who underwent the treatment, either as standalone or combined with Cataract procedures.
“Minimally Invasive Micro Sclerostomy (MIMS)”, April 1, 2014, Ophthalmology Futures Forum, Tokyo, Japan.
“Developing a New Surgical Procedure for Glaucoma”, Annual Conference of the Israel Ophthalmology Society, May 14-15, 2014, Tel-Aviv, Israel.
"MIMS: Minimally Invasive Micro Sclerostomy", Emerging Medical Technologies (EMT) Summit, October 20, 2015, San Francisco, U.S.A.
"MIMS: Minimally Invasive Micro Sclerostomy", China Israel Technology Innovation & Investment Summit, January 4-6, 2016, Bejing, China.
"MIMS: Minimally Invasive Micro Sclerostomy", Glaucoma 360 - 5th Annual New Horizons Forum, January 29, 2016, San Francisco, U.S.A.
"Combined phacoemulsification and minimally invasive microsclerostomy (MIMS - Sanoculis) procedure in cataract - glaucoma patients - report of short term follow-up in the first 15 cases", Annual Conference on Ocular Microsurgery 2017, January 12, 2017, Eilat, Israel.